Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO
May 31, 2020 10:30 ET
|
Tempus
CHICAGO, May 31, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch...
Tempus’ TIME Trial™ Program Reaches Critical Scale and Operational Milestones
May 29, 2020 15:55 ET
|
Tempus
CHICAGO, May 29, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a...
myCare Clinical Studies Show Cellworks Singula™ Achieves Superior Therapy Response Predictions for Brain Cancer Patients
May 29, 2020 08:00 ET
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Blood Advances发表Cellworks前瞻性基因组生物模拟研究，预测癌症治疗反应的准确率达到90%
September 19, 2019 12:13 ET
|
Cellworks Group, Inc.
旧金山, Sept. 20, 2019 (GLOBE NEWSWIRE) -- 精密医学领先机构及肿瘤治疗应答指数检测（TRI）技术的全球先锋企业 Cellworks 集团今天宣布：美国血液学会（ASH）期刊《Blood Advances》刊登了 iCare...
Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy
September 19, 2019 12:13 ET
|
Cellworks Group, Inc.
SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a leader in Precision Medicine and a global pioneer of Therapy Response Index (TRI) technology, today announced that Blood...
Massive Bio to Present SYNERGY-AI Trial-in-Progress Poster Presentation at Upcoming AACR 2019 using its AI Clinical Trial Matching Technology, and Announces Strategic Partnership in Precision Oncology with US-Based Admera Health
April 02, 2019 10:02 ET
|
Admera Health, LLC
NEW YORK, April 02, 2019 (GLOBE NEWSWIRE) -- Massive Bio, Inc., a leader in providing simplified and affordable access to clinical trials and precision oncology to cancer patients treated at...
SEngine Precision Medicine Announces Pulitzer Prize Winner and Pioneering Oncologist Dr. Siddhartha Mukherjee to Join Scientific Advisory Board
February 05, 2019 08:15 ET
|
SEngine Precision Medicine
SEATTLE, Feb. 05, 2019 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a biotech startup redefining how cancer is managed and accelerating life-saving discoveries through the promise of precision...
SEngine Precision Medicine Announces Nobel Prize Winner and Former Fred Hutch Cancer Research Center President Dr. Leland Hartwell to Join Board of Directors
October 29, 2018 10:15 ET
|
SEngine Precision Medicine
SEATTLE, Oct. 29, 2018 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a biotech startup delivering on the promise of precision oncology through functional genomics, today welcomed Dr. Leland (Lee)...
Tempus Unveils Tempus O, a Platform to Structure and Annotate Clinical Data at Scale
December 07, 2017 12:22 ET
|
Tempus
CHICAGO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data...